JPWO2021222342A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2021222342A5 JPWO2021222342A5 JP2022566066A JP2022566066A JPWO2021222342A5 JP WO2021222342 A5 JPWO2021222342 A5 JP WO2021222342A5 JP 2022566066 A JP2022566066 A JP 2022566066A JP 2022566066 A JP2022566066 A JP 2022566066A JP WO2021222342 A5 JPWO2021222342 A5 JP WO2021222342A5
- Authority
- JP
- Japan
- Prior art keywords
- dose
- compound
- subject
- formula
- administering
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000001875 compounds Chemical class 0.000 claims description 74
- 238000000034 method Methods 0.000 claims description 46
- 150000003839 salts Chemical class 0.000 claims description 32
- 239000000203 mixture Substances 0.000 claims description 20
- 102000003691 T-Type Calcium Channels Human genes 0.000 claims description 6
- 108090000030 T-Type Calcium Channels Proteins 0.000 claims description 6
- 230000002159 abnormal effect Effects 0.000 claims description 6
- 230000007488 abnormal function Effects 0.000 claims description 6
- 201000010099 disease Diseases 0.000 claims description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 6
- 206010044565 Tremor Diseases 0.000 claims description 4
- 201000006517 essential tremor Diseases 0.000 claims description 2
- 229920000642 polymer Polymers 0.000 description 4
- 206010015037 epilepsy Diseases 0.000 description 2
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 2
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 2
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 2
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical group OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 2
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- 208000024658 Epilepsy syndrome Diseases 0.000 description 1
- 208000002877 Epileptic Syndromes Diseases 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 229920000058 polyacrylate Polymers 0.000 description 1
- 208000020016 psychiatric disease Diseases 0.000 description 1
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063017140P | 2020-04-29 | 2020-04-29 | |
| US63/017,140 | 2020-04-29 | ||
| US202063050410P | 2020-07-10 | 2020-07-10 | |
| US63/050,410 | 2020-07-10 | ||
| US202063082946P | 2020-09-24 | 2020-09-24 | |
| US63/082,946 | 2020-09-24 | ||
| PCT/US2021/029539 WO2021222342A1 (en) | 2020-04-29 | 2021-04-28 | Methods of use of t-type calcium channel modulators |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023524039A JP2023524039A (ja) | 2023-06-08 |
| JP2023524039A5 JP2023524039A5 (https=) | 2024-05-09 |
| JPWO2021222342A5 true JPWO2021222342A5 (https=) | 2024-05-09 |
Family
ID=78373913
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022566066A Pending JP2023524039A (ja) | 2020-04-29 | 2021-04-28 | Ｔ型カルシウムチャネルモジュレーターを使用する方法 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20230165847A1 (https=) |
| EP (1) | EP4142764A4 (https=) |
| JP (1) | JP2023524039A (https=) |
| KR (1) | KR20230018384A (https=) |
| CN (1) | CN115776894A (https=) |
| AU (1) | AU2021263804A1 (https=) |
| BR (1) | BR112022021946A2 (https=) |
| CA (1) | CA3177277A1 (https=) |
| IL (1) | IL297642A (https=) |
| MX (1) | MX2022013595A (https=) |
| WO (1) | WO2021222342A1 (https=) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114340670B (zh) | 2019-07-11 | 2026-02-17 | 普拉克西斯精密药物股份有限公司 | T-型钙通道调节剂的制剂及其使用方法 |
| US20250170114A1 (en) * | 2022-02-03 | 2025-05-29 | Praxis Precision Medicines, Inc. | Methods of treatment using t-type calcium channel modulators |
| AU2023244348A1 (en) * | 2022-03-28 | 2024-10-10 | Praxis Precision Medicines, Inc. | Methods of using oligomeric compounds to treat scn2a-related disorders |
| EP4522271A4 (en) * | 2022-05-09 | 2026-04-29 | Praxis Prec Medicines Inc | Methods of use of t-type calcium channel modulators |
| EP4673219A1 (en) * | 2023-03-02 | 2026-01-07 | Praxis Precision Medicines, Inc. | Crystalline salt forms of n-((1-(2-(tert-butylamino)-2-oxoethyl)piperidin-4-yl)methyl)-3-chloro-5-fluorobenzamide and methods of use thereof |
| AU2024229946A1 (en) * | 2023-03-02 | 2025-09-11 | Praxis Precision Medicines, Inc. | Crystalline salts of a t-type calcium channel modulator and methods of use thereof |
| WO2025188619A1 (en) * | 2024-03-04 | 2025-09-12 | Praxis Precision Medicines, Inc. | Methods of treating parkinson's disease with t-type calcium channel modulators |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8377968B2 (en) * | 2008-06-02 | 2013-02-19 | Zalicus Pharmaceuticals, Ltd. | N-piperidinyl acetamide derivatives as calcium channel blockers |
| JP6957460B2 (ja) * | 2015-10-22 | 2021-11-02 | カビオン・インコーポレイテッドＣａｖｉｏｎ， Ｉｎｃ． | アンジェルマン症候群および関連する障害の処置方法 |
| WO2017083867A1 (en) * | 2015-11-12 | 2017-05-18 | Afasci, Inc. | Ion channel inhibitory compounds, pharmaceutical formulations and uses |
| CN110072521B (zh) * | 2016-12-16 | 2022-11-29 | 爱杜西亚药品有限公司 | 包含t型钙通道阻断剂的药物组合 |
| WO2018118101A1 (en) * | 2016-12-21 | 2018-06-28 | Praxis Precision Medicines, Inc. | T-type calcium channel modulators and methods of use thereof |
| AU2018364659A1 (en) * | 2017-11-10 | 2020-05-28 | Marinus Pharmaceuticals, Inc. | Ganaxolone for use in treating genetic epileptic disoders |
| IL300798B2 (en) * | 2018-10-03 | 2025-09-01 | Cavion Inc | Treatment of skeletal tremor with (r)–2-(4–isopropylphenyl)–n-(1-(5-(2,2,2–trifluoroethoxy)pyridin-2-yl)ethyl)acetamide |
| CN114340670B (zh) * | 2019-07-11 | 2026-02-17 | 普拉克西斯精密药物股份有限公司 | T-型钙通道调节剂的制剂及其使用方法 |
| EP4522271A4 (en) * | 2022-05-09 | 2026-04-29 | Praxis Prec Medicines Inc | Methods of use of t-type calcium channel modulators |
-
2021
- 2021-04-28 CN CN202180046763.8A patent/CN115776894A/zh active Pending
- 2021-04-28 EP EP21795254.8A patent/EP4142764A4/en active Pending
- 2021-04-28 KR KR1020227041859A patent/KR20230018384A/ko active Pending
- 2021-04-28 MX MX2022013595A patent/MX2022013595A/es unknown
- 2021-04-28 IL IL297642A patent/IL297642A/en unknown
- 2021-04-28 AU AU2021263804A patent/AU2021263804A1/en active Pending
- 2021-04-28 CA CA3177277A patent/CA3177277A1/en active Pending
- 2021-04-28 JP JP2022566066A patent/JP2023524039A/ja active Pending
- 2021-04-28 BR BR112022021946A patent/BR112022021946A2/pt unknown
- 2021-04-28 WO PCT/US2021/029539 patent/WO2021222342A1/en not_active Ceased
-
2022
- 2022-10-27 US US17/975,457 patent/US20230165847A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR100566701B1 (ko) | 고위험의 내당력 장애를 치료하기 위한 알파-글루코시다제억제제의 용도 | |
| TW389696B (en) | Accelerated release composition containing bromocriptine | |
| CN1142775C (zh) | 金刚烷衍生物在制备治疗内耳疾病的药物中的用途 | |
| TWI335217B (en) | Pharmaceutical formulations of modafinil | |
| JP2024074963A5 (https=) | ||
| JP2024075655A5 (ja) | 鏡像異性体的に純粋なブプロピオンの医薬の製造における使用 | |
| CN117120045A (zh) | 帕金森病的治疗方法 | |
| CA2389928A1 (en) | Method for treating diabetes | |
| WO2020099926A1 (en) | A method for treating pulmonary arterial hypertension and associated pulmonary arterial hypertension | |
| JPWO2021222342A5 (https=) | ||
| US20200188398A1 (en) | Method for treating sarcoidosis-associated pulmonary hypertension | |
| US11439613B2 (en) | Levodopa fractionated dose composition and use | |
| US5985933A (en) | Methods for treating central and peripheral nerve pain | |
| IL307751B1 (en) | Treatment of lupus nephritis with anti-type i inf receptor antibody anifrolumab | |
| JP2008540405A5 (https=) | ||
| RU2192252C2 (ru) | Применение прамипексола в лечении синдрома усталых ног | |
| US20190134023A1 (en) | Method of Restoring the Incretin Effect | |
| US4260600A (en) | Method of treating depression | |
| KR20080108515A (ko) | 고혈압의 치료를 위한 레닌 억제제 | |
| CN111432812A (zh) | 用于预防、减轻或治疗失神发作或显示失神发作的癫痫的氨基甲酸酯化合物的用途 | |
| US12161612B2 (en) | Methods and compositions for reducing symptoms of Parkinson's disease | |
| JP2021509671A5 (https=) | ||
| EP4694877A1 (en) | Methods and compositions for reducing symptoms of parkinson's disease | |
| JP4974057B2 (ja) | 血糖降下剤を含有する、耐糖能異常、境界型糖尿病、インスリン抵抗性及び高インスリン血症の改善ないし治療用医薬組成物 | |
| JP2026512887A (ja) | パーキンソン病の症状を低下させるための方法および組成物 |